Overexpression of SMYD3 in breast cancer, with its impaired function leading to inhibition of cell cycle progression of breast cancer cells in vitro, through induction of cell cycle arrest of G0/G1 [69, 70]; mechanistically SMYD3 promotes breast carcinogenesis by transcriptionally activating oncogenes like WNT10B, N-myc, CrkL, RIZ and hTERT, cell cycle regulatory genes (cyclin G1, CDK2) and signal transduction pathway components (STAT1, MAP3K11, PIK3CB) [70]. The gene discussed is MYCN; the disease is breast cancer.